French drug maker Sanofi SA, pressing forward with a global realignment, Monday notified about three dozen research and development employees in Massachusetts that their jobs will be eliminated, according to employees.
The jobs are in labs supporting the biosurgery, bone and joint disease, drug delivery discovery, and biomaterial engineering groups that were formerly part of Genzyme Corp., the employees said. Those labs are in Cambridge, Framingham, and Waltham.
Sanofi paid $20.1 billion to acquire Cambridge-based Genzyme in 2011 and has renamed the division Sanofi Genzyme. In a global restructuring that began last summer, Sanofi shifted oversight for research and development jobs in Massachusetts and elsewhere to a corporate research organization based in Paris.
A spokeswoman said Monday that she couldn’t immediately comment on the cuts. Sanofi told its labor unions earlier this month that it is paring about 600 jobs in France. The company has not confirmed cuts at other locations.
By Robert Weisman
Source: Boston Globe
Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.
The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.
In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.
